Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ripretinib - Deciphera Pharmaceuticals

Next Previous
Drug Profile

Ripretinib - Deciphera Pharmaceuticals

Alternative Names: DCC-2618; QINLOCK

Latest Information Update: 02 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Deciphera Pharmaceuticals; Specialised Therapeutics Asia; ZAI Lab
  • Class Amines; Antineoplastics; Bromobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Naphthyridines; Phenylurea compounds; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein B-raf inhibitors; Proto-oncogene protein c-kit expression inhibitors; TIE-2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Glioblastoma; Anaplastic astrocytoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastrointestinal stromal tumours
  • No development reported Glioblastoma; Solid tumours; Systemic mastocytosis

Most Recent Events

  • 07 Jul 2026 Phase-I clinical trials in Gastrointestinal stromal tumours (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in Japan (PO) (NCT07618377)
  • 02 Jun 2026 Pharmacokinetics and adverse events data from a phase I trial in Gastrointestinal stromal tumors presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 01 Jun 2026 Ono Pharmaceutical plans a phase I trial for Gastrointestinal stromal tumors (Second-line therapy or greater; Inoperable or unresectable, Metastatic disease, Recurrent) in Japan in July 2026 (PO) (NCT07618377)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top